Increased mucin 1 expression in recurrence and malignant transformation of salivary gland pleomorphic adenoma

Histopathology

Volumn 58, Issue 3, 2011, Pages 377-382

  Soares, Andresa Borges ^a   Demasi, Ana Paula Dias ^a   Altemani, Albina ^b   De Araújo, Vera Cavalcanti ^a  

^a SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Carcinoma ex adenoma; MUC1; Pleomorphic; Pleomorphic adenoma; Recurrence

Indexed keywords

MUCIN 1;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; SALIVARY GLAND PLEOMORPHIC ADENOMA;

ADENOCARCINOMA; ADENOMA, PLEOMORPHIC; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; MUCIN-1; NEOPLASM RECURRENCE, LOCAL; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS;

EID: 79952075961     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03758.x     Document Type: Article

References (34)

1. Chen AM, Garcia J, Bucci MK, Quivey JM, Eisele DW. Recurrent pleomorphic adenoma of the parotid gland: long-term outcome of patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66; 1031-1035.
2. Henriksson G, Westrin KM, Carlsoo B, Silfversward C. Recurrent primary pleomorphic adenomas of salivary gland origin: intrasurgical rupture, histopathologic features, and pseudopodia. Cancer 1998; 82; 617-620.
3. Maxwell EL, Hall FT, Freeman JL. Recurrent pleomorphic adenoma of the parotid gland. J. Otolaryngol. 2004; 33; 181-184.
4. Zbaren P, Tschumi I, Nuyens M, Stauffer E. Recurrent pleomorphic adenoma of the parotid gland. Am. J. Surg. 2005; 189; 203-207.
5. Duck SW, McConnel FM. Malignant degeneration of pleomorphic adenoma - clinical implications. Am. J. Otolaryngol. 1993; 14; 175-178.
6. Fleming WB. Recurrent pleomorphic adenoma of the parotid. ANZ J. Surg. 1987; 57; 173-176.
7. Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 2008; 8; 3329-3341.
8. Morrison C, Merati K, Marsh WL Jr et al. The mucin expression profile of endometrial carcinoma and correlation with clinical-pathologic parameters. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 426-431.
9. Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 1994; 106; 353-361.
10. Hiraga Y, Tanaka S, Haruma K et al. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998; 55; 307-319.
11. Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am. J. Surg. Pathol. 2002; 26; 466-471.
12. Kashiwagi H, Kijima H, Dowaki S et al. DF3 expression in human gallbladder carcinoma: significance for lymphatic invasion. Int. J. Oncol. 2000; 16; 455-459.
13. Handra-Luca A, Lamas G, Bertrand JC, Fouret P. MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications. Am. J. Surg. Pathol. 2005; 29; 881-889.
14. Nitta T, Sugihara K, Tsuyama S, Murata F. Immunohistochemical study of MUC1 mucin in premalignant oral lesions and oral squamous cell carcinoma: association with disease progression, mode of invasion, and lymph node metastasis. Cancer 2000; 88; 245-254.
15. Hamada T, Matsukita S, Goto M et al. Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence. J. Clin. Pathol. 2004; 57; 813-821.
16. Mannweiler S, Beham A, Langner C. MUC1 and MUC2 expression in salivary gland tumors and in non-neoplastic salivary gland tissue. APMIS 2003; 111; 978-984.
17. Brieger J, Duesterhoeft A, Brochhausen C, Gosepath J, Kirkpatrick CJ, Mann WJ. Recurrence of pleomorphic adenoma of the parotid gland - predictive value of cadherin-11 and fascin. APMIS 2008; 116; 1050-1057.
18. Ghosh S, Panarese A, Bull PD, Lee JA. Marginally excised parotid pleomorphic salivary adenomas: risk factors for recurrence and management. A 12.5-year mean follow-up study of histologically marginal excisions. Clin. Otolaryngol. Allied Sci. 2003; 28; 262-266.
19. Stennert E, Wittekindt C, Klussmann JP, Arnold G, Guntinas-Lichius O. Recurrent pleomorphic adenoma of the parotid gland: a prospective histopathological and immunohistochemical study. Laryngoscope 2004; 114; 158-163.
20. Laskawi R, Schott T, Schroder M. Recurrent pleomorphic adenomas of the parotid gland: clinical evaluation and long-term follow-up. Br. J. Oral Maxillofac. Surg. 1998; 36; 48-51.
21. Hanisch FG, Muller S. MUC1: the polymorphic appearance of a human mucin. Glycobiology 2000; 10; 439-449.
22. Liu B, Lague JR, Nunes DP et al. Expression of membrane-associated mucins MUC1 and MUC4 in major human salivary glands. J. Histochem. Cytochem. 2002; 50; 811-820.
23. Niv Y. MUC1 and colorectal cancer pathophysiology considerations. World J. Gastroenterol. 2008; 14; 2139-2141.
24. Denda-Nagai K, Irimura T. MUC1 in carcinoma-host interactions. Glycoconj. J. 2000; 17; 649-658.
25. Ligtenberg MJ, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 1992; 52; 2318-2324.
26. Makiguchi Y, Hinoda Y, Imai K. Effect of MUC1 mucin, an anti-adhesion molecule, on tumor cell growth. Jpn. J. Cancer Res. 1996; 87; 505-511.
27. Kondo K, Kohno N, Yokoyama A, Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 1998; 58; 2014-2019.
28. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell 1996; 7; 565-577.
29. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 1995; 129; 255-265.
30. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993; 151; 767-776.
31. Araujo VC, Demasi AP, Furuse C et al. Collagen type I may influence the expression of E-cadherin and beta-catenin in carcinoma ex-pleomorphic adenoma. Appl. Immunohistochem. Mol. Morphol. 2009; 17; 312-318.
32. Yin L, Kharbanda S, Kufe D. Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia. J. Biol. Chem. 2007; 282; 257-266.
33. Shimizu M, Imai M. Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro. Biol. Pharm. Bull. 2008; 31; 2288-2293.
34. Xu Y, Zhang L, Hu G. Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis. Biologicals 2009; 37; 18-25.